Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christine Frissora

Gastroenterology New York, NY Medical Doctor

NPI 1861589954 CMS profile 356751

525 E 68Th St # J-314, New York, NY 10021

Open in the dashboard

General payments

$123,078

344 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christine Frissora of New York, NY is reported in the CMS Open Payments database as having received $123,078 across 344 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34,422 83
2024 General $23,185 68
2023 General $16,558 58
2022 General $9,684 34
2021 General $21,539 40
2020 General $11,062 26
2019 General $6,627 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christine Frissora
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Christine Frissora were reported at $34,422. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Christine Frissora Gastroenterology median Middle half National median
2019 $6,627 $417 $126–$1,100 $163
2020 $11,062 $224 $74–$624 $114
2021 $21,539 $352 $106–$1,054 $132
2022 $9,684 $448 $129–$1,270 $149
2023 $16,558 $533 $150–$1,390 $160
2024 $23,185 $605 $160–$1,606 $164
2025 $34,422 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. QOL Medical, LLC $102,415 177 payments
  2. Phathom Pharmaceuticals, Inc. $12,011 22 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,602 5 payments
  4. Ardelyx, Inc. $2,052 19 payments
  5. AbbVie, Inc. $1,217 58 payments
  6. Mahana Therapeutics, Inc. $877 2 payments
  7. Alfasigma USA, Inc. $500 1 payment
  8. Takeda Pharmaceuticals U.S.A., Inc. $360 22 payments
  9. Janssen Biotech, Inc. $241 8 payments
  10. Regeneron Healthcare Solutions, Inc. $125 1 payment
  11. Other $679 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $47,100 18 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45,450 24 payments
  3. Travel and Lodging $13,967 56 payments
  4. Food and Beverage $8,961 243 payments
  5. Consulting Fee $5,200 2 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,400 1 payment
Products named General payments · program years 2019–2025
  1. Sucraid Therapy For Csid $38,938 95 payments
  2. Sucraid Genetic Disease $33,504 42 payments
  3. Sucraid Therapy For Csid $29,973 40 payments
  4. VOQUEZNA $11,966 18 payments
  5. XIFAXAN $2,561 3 payments
  6. IBSRELA $2,052 19 payments
  7. RINVOQ $648 23 payments
  8. Zelnorm $500 1 payment
  9. LINZESS $437 29 payments
  10. CREON $398 25 payments
  11. Other $1,940 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

321

Median for Gastroenterology: 569

Drug cost

$75,586

Median for Gastroenterology: $104,976

Branded share of claims

49.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 59 $43,946
Trulance Plecanatide Brand 31 $18,649
Nexium Esomeprazole Magnesium Brand 20 $8,136
Cholestyramine Cholestyramine (With Sugar) Brand 14 $1,739
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 36 $598
Lactulose Generic 12 $590
Famotidine Generic 44 $575
Omeprazole Generic 40 $541
Pantoprazole Sodium Generic 35 $523
Gabapentin Generic 12 $165

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$55,219

Medicare's payments for the services billed

Medicare patients

296

Average age 74

Services billed

473

222 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 58%
Osteoporosis 40%
Ischemic heart disease 27%
Diabetes 23%
Cancer 23%
Depression 22%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $12,011
$12,011 — —
Sucraid
  • QOL Medical, LLC $10,560
$10,560 — —
TREMFYA
  • Janssen Biotech, Inc. $94
$94 — —
CREON
  • AbbVie, Inc. $77
$77 — —
LINZESS
  • AbbVie, Inc. $62
$62 59 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record